Document is current

Article History

Received: 8 February 2024

Accepted: 29 May 2024

First Online: 10 July 2024

Declarations

:

: A.A. has received research grants from Bayer, MSD, BMS, Arcus and Roche. A.A. has also received speaker honorarium from Novartis, MSD, and BMS. A.A. has received travel grants from MSD and Astra-Zeneca. A.A. has reported a consultative role from BMS, Bayer, MSD, and Astra-Zeneca. T.M. has received honoraria for speaking or consulting roles from Servier, Pierre Fabre, Merck Serono, AAA, Sanofi, Galapagos, and research grants from Amgen and Roche. T.M. has also received travel grants from Pierre Fabre, Merck Serono, and Sanofi. L.E. has received speaker honorarium from Astrellas, Pierre Fabre, and Merck. L.E. has also received travel grants from MSD, Servier, BMS, and Merck. L.E. has reported a consultative role from Astrellas. F.G., L.G., A.E., P.C., A.M., S.G., M.Y declare that they have no conflict of interest.

: The study was conducted following the principles of the Declaration of Helsinki and the International Conference on Harmonization and Good Clinical Practice guidelines. The study protocol (ClinicalTrials.gov identifier: NCT03828799; EudraCT identifier: 2018-003541-42), including all amendments, was reviewed and approved by the French ethics committee (CPP Est III) on December 4, 2018, and the French National Agency for the Safety of Health Products (ANSM) on November 21, 2018.

: Not applicable.

: Patients provided their written informed consent before enrollment in the study.